STAT+: Pharmalittle: Biogen R&D chief retiring amid controversy over Alzheimer’s drug; Pfizer strikes deal for generic versions of its Covid pill
Top of the morning to you, and a fine one it is. Crystal clear blue skies and a nippy breeze are enveloping the Pharmalot campus this morning, where the official mascot eagerly awaits the start of yet another play date and we are brewing needed cups of stimulation. Our choice today is peppermint mocha. Yum. We are, however, otherwise busy foraging for fascinating and juicy developments. So please keep us in mind when news crosses your own path. But we would be remiss if we did not remind you that a STAT Summit gets under way today with a cast of interesting folks. Meanwhile, here are a few items to get you going. …
Al Sandrock, the top scientist at Biogen (BIIB) and the face of its years-long campaign to develop a treatment for Alzheimer’s disease, is leaving the company after more than two decades, STAT reports. The surprise departure leaves a void in the upper ranks and comes as Biogen faces a worsening business outlook. The company is saddled with a string of setbacks to its research pipeline and is being forced to defend its scientific integrity after the approval of the polarizing Alzheimer’s treatment Aduhelm. Priya Singhal, Biogen’s senior vice president of global safety and regulatory sciences, will replace him on an interim basis.
Continue to STAT+ to read the full story…
